Ani AE, Daylop YB, Agbaji O & Idoko J (2009). Drug susceptibility test of Mycobacterium
tuberculosis by nitrate reductase assay. Journal of Infection in Developing Countries
3: 16–
19.</p>
Bello LA, Shittu MO, Shittu BT, Oluremi AS, Akinnuroju ON, Adekola SA. Rifampicin-
monoresistant Mycobacterium tuberculosis among the patients visiting chest clinic,
state
specialist hospital, Akure, Nigeria. Int J Res Med Sci. 2014; 2:1134–1137.
Breathnach, A.S., de Ruiter, A., Holdsworth, G.M., Bateman, N.T., O’Sullivan, D.G
and Rees,
P.J. (2008). An outbreak of multidrug resistant tuberculosis in a London teaching
hospital.
J. Hosp. Infect. 39:111-7.
Chaulet, P., Boulahbal, F., and Grosset, J. (2015). Surveillance of drug resistance
for tuberculosis control: why and how? Tuberc. Lung Dis. 76 (6): 487-492.
Crofton, J., Chauletxs nx, P., and Maher. D (2012). Guidelines for the management
of drug-
resistant tuberculosis. WHO/TB/96.210 (Rev.1). World Health Organization, Geneva,
Switzerland.</p>
Canetti, G., Fox, W., Khomenko, A., Mahler, H.T., Menon, N.K., Mitchison, D.A., et al., (1969).
Advances in techniques of testing mycobacterial drug sensitivity, and the use of
sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41: 21-43.
Canetti, G., Froman, S., Grosset, J et al., (1963). Mycobacteria: laboratory methods for testing
drug sensitivity and resistance. Bull World Health Organ 29: 565-78.
Chaulet, P., Boulahbal, F., and Grosset, J. (1995). Surveillance of drug resistance
for
tuberculosis control: why and how? Tuberc. Lung Dis. 76 (6): 487-492.
Cohn, D.L., Bustreo, F., and M.C. Raviglione (1997). Drug-resistant tuberculosis:
review of
worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin. Infect.
Dis. 24 Suppl 1, S121-S130.
Crofton, J., Chauletxs nx, P., and Maher. D (1997). Guidelines for the management
of drug-
resistant tuberculosis. WHO/TB/96.210 (Rev.1). World Health Organization, Geneva,
Switzerland.</p>
Crofton, J. (1994). Multidrug resistance: danger for the Third World. In Porter JDH,
McAdam,
KDNJ. Editors: “Tuberculosis back to the future”, Chichester, John Wiley & Sons Ltd.,
231-233.</p>
Crofton, J and Mitchison, D.A. (1948). Streptomycin resistance in pulmonary tuberculosis.
Brit.
Med. J. 2:1009-1015.
Barnes, P.F., and Barrows, S.A (1993). Tuberculosis in the 1990’s. Ann Intern Med 119: 400-10.
Bloch, A.B., Cauthen, G.M., and Onorato, I.M. (1994). Nationwide survey of drug-resistant
tuberculosis in the United States. <em>J. Amer. Med. Assoc. 271</em>:665-671.</p>
Breathnach, A.S., de Ruiter, A., Holdsworth, G.M., Bateman, N.T., O’Sullivan, D.G
and Rees,
P.J. (1998). An outbreak of multidrug resistant tuberculosis in a London teaching
hospital.
J. Hosp. Infect. 39:111-7.
Braun, M.M., Kilburn, J.O., Smithwick, R.W, et al., (1992). HIV infection and primary
resistance to antituberculosis drugs in Abidjan, Cote d’Ivoire. AIDS 6: 1327-1330.
Dye, C., Hosseini, M., and C. Watt (2007). Did we reach the 2005 target hjhijio for
tuberculosis
control? Bull World Health Organ 85: 364-9.
Donald, E., and A. V. Rie (2006).XDR tuberculosis: an indicator of public health
Negligence. Lancet 368:1554–1556.
Drobniewski, F., Eltringham, I., Graham, C., Magee, J.G., Smith, E.G and Watt, B.
(2002). A
national study of clinical and laboratory factors affecting the survival of patients
with
multiple drug resistant tuberculosis in the UK. Thorax 57: 810-6.
Dye, C., Hosseini, M., and C. Watt (2007). Did we reach the 2005 target hjhijio for
tuberculosis
control? Bull World Health Organ 85: 364-9.
Espinal, M.A., Adalbert, P.H., Laszlo, A.L., et al., (2003). Global trends in resistance to
antituberculosis drugs. N Engl J Med 344: 1294-303.
Espinal, M.A., Laserson,K., Camacho, M., Fusheng, Z., Kim, S.J., Tlali, R.E., Smith,
I., Suarez,
P., Atunes, M.L George, A.G., Martin-Casabona, N., Simelane, P., Weyer, K., Binkin,
N.,
Raviglione, M,C (2001). Determinants of drug-resistant tuberculosis: analysis of
11
countries. Int J Tuberc Lung Dis 5(10): 887-893.
Raviglione, M,C (2001). Determinants of drug-resistant tuberculosis: analysis of
11
countries. Int J Tuberc Lung Dis 5(10): 887-893.
Gandhi, N. R., A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller,
J. Andrews,
and G. Friedland (2006). Extensively drug-resistant tuberculosis as a cause of death
in
patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet
368:1575–1580.
Grange, J.M., and Zuma, A (2002). The global emergency of tuberculosis: What is the
cause? J.
Royal Soc Health 122: 78-81.
Gupta, R., Kim, J.Y., Espinal, M.A., Caudron, J.M., Farmer, P.E., and Raviglione,
M.C. (2001).
Responding to market failures in tuberculosis: a model to increase access to drugs
and
treatment. Science 293:1049-51.
Horsburgh, C.R. (2000). The global problem of multidrug-resistant tuberculosis: The
genie is out
of the bottle. J. Amer. Med. Assoc. 283:2575-2576.
Idigbe EO, Duque JP, John EK, Annam O. Resistance to antituberculosis drugs in treated
patients
in Lagos, Nigeria. J Trop Med Hyg 1992;95:186-91.
Johnson, R., Streicher, E.M., Louw, G.E., Warren, R.M., van Helden, P.D., and Victor.T.C
(2007). Drug resistance in <em>Mycobacterium tuberculosis</em>. <em>Mol Biol 8</em>: 97-112. </p>
Jordaan R, A.M., Pretorius, L., Engelke, E., van der, S.G.,Kewley, C., Bosman, M.,
van Helden,
P.D., Warren, R., and Victor, T.C (2006). Ethambutol resistant testing by mutation
detection. <em>Int. J. </em>Johnson<em> Tuberc. Lung Dis 10</em>: 68-73.</p>
Kehinde AO, Adetoye AE. Diagnosis of pulmonary tuberculosis using genotype MTBDRPLUS
assay in three local government primary health centres of Osun State, Nigeria- a pilot
study.
J Med Microb Diagn. 2012; S3:001.</p>
Kenyon, T.A., Mwasekaga, M.J., Huebner, R., Rumisha, D., Binkin, N., and E. Maganu
(1999).
Low levels of drug resistance amidst rapidly increasing tuberculosis and human
immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 3(1): 4-11
Kochi, A., Vareldzis, B., Styblo, K. (1994). Multidrug resistant tuberculosis and
its control.
Res. Microbiol., 144: 104-110.
Lawson L, Yassin M A, Abdurrahman ST. et al., (2011). Resistance to first-line tuberculosis drugs
in three cities of Nigeria. Tropical Medicine and International Health 16 (8) pp 974–980
Moran, M. (2014). Running out of breath? TB care in the 21st century. MSF. pp. 1-32.
Kent, P. T., and G. P. Kubica (1985).Public health mycobacteriology: a guide for the
level III laboratory. Centers for Disease Control, Atlanta, GA.</p>
Moran, M. (2004). Running out of breath? TB care in the 21st century. MSF. pp. 1-32.
Nathanson, E., Lambregts-van, W.C., Rich, M.L., Gupta, R., Bayona, J., Blondal, K.,
et al., (2006).
Multi-drug resistant tuberculosis management in resource-limited settings. Emerg Infect
Dis 12: 1389-97.
Okodua M, Ihongbe J, Esumeh F. Pulmonary tuberculosis and resistance pattern to first
line
antituberculosis drugs in a city of western Nigeria. Int J Basic Appl Innov Res. 2012;
1:
48–56.
Oluwaseun E, Akinniyi AP, Afolabi O. Primary multi-drug resistant tuberculosis among
HIV
seropositive and seronegative patients in Abeokuta, southwestern Nigeria. Am J Res
Comm. 2013; 1:224–237.</p>
Prammananan, T., Arjatankool, W., Chaiprasert, A., Tingtoy, N., Leechawengwong, M.,
Aswapokee, N., Leelaramasae, A., and Dhiraputra, C (2005). Second-line susceptibilities
of Thai multidrug-resistant <em>Mycobacterium tuberculosis</em> isolates. <em>Intl J Tuberc Lung Dis.
9: </em>216-9.</p>
WHO (2010). Multidrug and Extensively Drug-Resistant TB (M⁄XDR-TB). 2010 Global Report
on Surveillance and Response. WHO, Geneva, Switzerland.</p>
World Health Organisation. Global Tuberculosis Control: WHO report 2016. Geneva,
Switzerland: World Health Organisation, 2016.